NASDAQ:PMVP

PMV Pharmaceuticals News Headlines

$31.26
+0.12 (+0.39 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$30.73
Now: $31.26
$31.78
50-Day Range
$30.66
MA: $35.46
$43.10
52-Week Range
$29.44
Now: $31.26
$63.22
Volume59,700 shs
Average Volume153,795 shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

PMV Pharmaceuticals (NASDAQ PMVP) News Headlines Today

SourceHeadline
Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of DirectorsAbeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors
benzinga.com - April 19 at 7:35 AM
PMV Pharmaceuticals (NASDAQ:PMVP) Sees Large Volume IncreasePMV Pharmaceuticals (NASDAQ:PMVP) Sees Large Volume Increase
americanbankingnews.com - April 15 at 11:40 AM
Thilo Schroeder Sells 3,903 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) StockThilo Schroeder Sells 3,903 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock
americanbankingnews.com - April 13 at 10:40 PM
PMV Pharmaceuticals (NASDAQ:PMVP) Shares Gap Down to $33.30PMV Pharmaceuticals (NASDAQ:PMVP) Shares Gap Down to $33.30
americanbankingnews.com - April 12 at 11:30 AM
PMV Pharma Presents Late-Breaking Preclinical...PMV Pharma Presents Late-Breaking Preclinical...
benzinga.com - April 10 at 6:16 PM
PMV Pharmaceuticals (NASDAQ:PMVP) Trading Up 2.8%PMV Pharmaceuticals (NASDAQ:PMVP) Trading Up 2.8%
americanbankingnews.com - April 9 at 12:32 PM
PMV Pharmaceuticals (NASDAQ:PMVP) Sees Strong Trading VolumePMV Pharmaceuticals (NASDAQ:PMVP) Sees Strong Trading Volume
americanbankingnews.com - April 5 at 11:42 AM
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Director Sells $69,894.10 in StockPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Director Sells $69,894.10 in Stock
americanbankingnews.com - March 31 at 11:12 PM
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Director Thilo Schroeder Sells 33,626 SharesPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Director Thilo Schroeder Sells 33,626 Shares
americanbankingnews.com - March 31 at 10:40 PM
PMV Pharmaceuticals (NASDAQ:PMVP) Hits New 12-Month Low at $30.15PMV Pharmaceuticals (NASDAQ:PMVP) Hits New 12-Month Low at $30.15
americanbankingnews.com - March 30 at 11:05 AM
PMV Pharmaceuticals (NASDAQ:PMVP)  Shares Down 6.4%  After Insider SellingPMV Pharmaceuticals (NASDAQ:PMVP) Shares Down 6.4% After Insider Selling
americanbankingnews.com - March 29 at 11:20 AM
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate HighlightsPMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
finance.yahoo.com - March 3 at 5:35 PM
PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory BoardPMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board
finance.yahoo.com - February 16 at 9:14 AM
Were Not Worried About PMV Pharmaceuticals (NASDAQ:PMVP) Cash BurnWe're Not Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn
finance.yahoo.com - December 25 at 3:10 PM
Is PMVP A Good Stock To Buy Now?Is PMVP A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 7:39 PM
PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx ConferencePMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference
finance.yahoo.com - November 24 at 7:14 PM
PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53
finance.yahoo.com - November 23 at 12:59 PM
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate HighlightsPMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
finance.yahoo.com - November 13 at 8:55 AM
PMV Pharmaceuticals Inc.PMV Pharmaceuticals Inc.
barrons.com - November 1 at 12:37 PM
PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C MutationPMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation
finance.yahoo.com - October 24 at 12:42 AM
PMV Pharmas PC14586 Fast Trackd for solid tumors with p53 Y220C mutationPMV Pharma's PC14586 Fast Track'd for solid tumors with p53 Y220C mutation
seekingalpha.com - October 13 at 4:59 PM
PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional SharesPMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
markets.businessinsider.com - October 1 at 11:30 AM
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.